Pharmaceutical composition used for preventing and treating colibacillosis in livestock and poultry

Abstract

The invention relates to a pharmaceutical composition used for preventing and treating colibacillosis in livestock and poultry. Every 100 g of the pharmaceutical composition comprises 2 to 10 g of ceftiofur hydrochloride, 0.25 to 10 g of tazobactam sodium, 5 to 10 g of probenecid sodium, 0.1 to 0.5 g of dexamethasone sodium phosphate and 2 to 15 g of beta-cyclodextrin, with the balance being pharmaceutically acceptable accessories. The pharmaceutical composition has the advantages of reasonable composition, low cost, a remarkable curative effect on clinical pathogenic escherichia coli, especially on drug-resistant intractable escherichia coli, a simple preparation method, stable properties and convenience in large scale intensive production.

Description

technical field [0001] The invention belongs to the field of veterinary drugs, in particular to a pharmaceutical composition for preventing and treating Escherichia coli diseases in livestock and poultry. Background technique [0002] Colibacillosis is a general term for a class of livestock and poultry diseases caused by some pathogenic strains of Escherichia coli. Escherichia coli is a conditional pathogenic bacterium that parasitizes almost all animals and forms a balance with the body most of the time. When the physiological functions of the body are out of balance, pathogenic E. coli can have a reproductive advantage. and lead to disease. The disease can occur all year round, and it is more likely to occur in winter and spring when the air humidity is relatively high or the climate is changeable. It mainly causes the disease of young livestock and poultry. Peritonitis, perihepatitis, air sacitis and diarrhea are the main symptoms. In recent years, with the developmen...

AI Technical Summary

Problems solved by technology

However, because it is insoluble in water and has poor stability, it is often made into ceftiofur sodium salt and ceftiofur hydrochloride to improve its stability and water solubility

With the wide application of ceftiofur in clinical practice, Escherichia coli has gradually developed serious drug resistance to ceftiofur. The main reason for bacterial resistance to ceftiofur is due to the production of extended-spectrum β- The drug resistance of these ESBLs-producing Escherichia coli often manifests as multi-drug resistance, that is, it is not only resistant to β-lactam antibiotics, but also resistant to non-β-lactam antibiotics, which has a negative impact on clinical treatment. Infectious diseases caused by ESBLs Escherichia coli pose a great threat

Images